Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036.v1

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.

What problem does this paper attempt to address?

Supplementary Figure 3 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.
Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers,Lixia Diao,Jing Wang,Pierre Saintigny,Luc Girard,Michael Peyton,Li Shen,Youhong Fan,Uma Giri,Praveen K. Tumula,Monique B. Nilsson,Jayanthi Gudikote,Hai Tran,Robert J.G. Cardnell,David J. Bearss,Steven L. Warner,Jason M. Foulks,Steven B. Kanner,Varsha Gandhi,Nancy Krett,Steven T. Rosen,Edward S. Kim,Roy S. Herbst,George R. Blumenschein,J. Jack Lee,Scott M. Lippman,K. Kian Ang,Gordon B. Mills,Waun K. Hong,John N. Weinstein,Ignacio I. Wistuba,Kevin R. Coombes,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22446704

2023-01-01

Abstract:PDF file - 66K, CDH1 probes vary in their accuracy and dynamic range
Supplementary Figure S1 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461797.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining results of immunohistochemistry.
Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Jiannong Li,Inna Smalley,Zhihua Chen,Jheng-Yu Wu,Manali S. Phadke,Jamie K. Teer,Thanh Nguyen,Florian A. Karreth,John M. Koomen,Amod A. Sarnaik,Jonathan S. Zager,Nikhil I. Khushalani,Ahmad A. Tarhini,Vernon K. Sondak,Paulo C. Rodriguez,Jane L. Messina,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22486712

2023-01-01

Abstract:Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy
Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461794

2023-01-01

Abstract:Supplementary Figure S2. Overall survival of melanoma patients in relation to mTOR nonsynonymous mutations.
Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2
Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461795

2023-01-01

Abstract:Kaplan-Meier survival curves for relapse free and overall survival according to EGFR, KRAS, BRAF, HER2, FGFR or wild-type status
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong,Xinan Sheng,Xianliang Wu,Junya Yan,Meng Ma,Jihong Yu,Lu Si,Zhihong Chen,Chuanliang Cui,Jie Dai,Yiqian Li,Huan Yu,Teng Xu,Huan Tang,Bixia Tang,Lili Mao,Bin Lian,Xuan Wang,Xieqiao Yan,Siming Li,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22463072.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining of CDK4 pathway-related proteins Supplementary Figure S2. Sensitivity of acral melanoma cells to CDK4/6 inhibitors. Supplementary Figure S3. Western blotting assays of total Rb and phosphorylated Rb (pRb) in cell lines after CDK4/6 inhibitor treatments Supplementary Figure S4. Representative images of tumor nodules after the treatments. Supplementary Figure S5. Rb inactivation status in PDX models after AT7519 and PD0332991 treatments.
Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396160

2023-01-01

Abstract:PDF file - 407K, DNA damage induced by BRAFV600E in human melanoma cells.
Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Y. Kong,L. Si,J. Guo,Z. H. Chi,C. L. Cui,X. N. Sheng,B. X. Tang

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8568

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:8568 Background: Mutations in KIT, BRAF, NRAS and PDGFRA are common in melanoma, which have not been extensively studied in Asia. We examined these aberrations and correlated the aberrations to the clinical features and survival in Asian melanoma patients. Methods: This study involved samples from 644 melanoma patients in Peking University Cancer Hospital. Clinical data were collected. Tissue samples were analyzed for mutations in KIT (exons 9,11,13,17,18), BRAF (exons 11,15), NRAS (exons1,2) and PDGFRA (exons 12,14,18) genes by PCR amplification and Sanger sequencing. The copy numbers of KIT gene were analyzed by quantitative PCR. Results: The incidence of somatic mutations within the KIT, BRAF, NRAS and PDGFRA genes was 10.1% (58/573), 25.9% (121/468), 7.2% (33/459) and 4.8% (17/352), respectively. The incidence of increased KIT copy number was 7.6% (39/516). The highest KIT mutation frequency is within the CSD subgroup (27.3%, 9/33). Increased KIT gene copy number was comparatively more frequent in acral (8.0%, 14/176) and mucosal (11.5%, 17/148) melanomas than in CSD (3.2%, 1/31) and Non-CSD (1.9%, 2/104) melanomas. Surprisingly, BRAF mutations were detected in 17.9% (28/156) of acral melanomas and 12.5% (16/128) of mucosal melanomas. The most frequent mutation in BRAF was V600E (87.3%). The median follow-up period was 24 (3~229) months (n=473). No statistical differences were found for thickness and ulceration rates between melanomas with or without these mutations (P=0.6). The median survival for patients with KIT mutations (30 months) and BRAF (33m) were significantly shorter than for patients with WT tumors (53m; P=0.01, P=0.005 respectively). Overall survivals were similar in groups with or without NRAS and PDGFRA mutations. Conclusions: KIT and BRAF are important oncogenes in Asian melanomas. Mutations in the BRAF gene were more common than KIT mutations. For the first time, our study suggests that genetic KIT and BRAF aberration is an adverse prognostic factor for melanoma. These results suggest that the KIT inhibitor as well as BRAF V600E inhibitor might play their roles in Asian melanoma patients. Supported by the National Natural Science Foundation of China30973483.
Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396163

2023-01-01

Abstract:PDF file - 343K, p53 function in BRAFV600E/ARF-/- murine melanoma cells.
Figure S1 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Jiayi Yu,Junya Yan,Qian Guo,Zhihong Chi,Bixia Tang,Bin Zheng,Jinyu Yu,Ting Yin,Zhiyuan Cheng,Xiaowen Wu,Huan Yu,Jie Dai,Xinan Sheng,Lu Si,Chuanliang Cui,Xue Bai,Lili Mao,Bin Lian,Xuan Wang,Xieqia Yan,Siming Li,Li Zhou,Keith T. Flaherty,Jun Guo,Yan Kong

DOI: https://doi.org/10.1158/1078-0432.22472378

2023-01-01

Abstract:Supplementary Figure S1. The flow chart describing the total population of the study.
Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Jingqiang Wang,Takashi Kobayashi,Nicolas Floc'h,Carolyn Waugh Kinkade,Alvaro Aytes,David Dankort,Celine Lefebvre,Antonina Mitrofanova,Robert D. Cardiff,Martin McMahon,Andrea Califano,Michael M. Shen,Cory Abate-Shen

DOI: https://doi.org/10.1158/0008-5472.22394105

2023-01-01

Abstract:PDF file - 404K, Supplementary Figure 1: Strategy for inducible recombination in the prostate. Supplementary Figure 2: Analyses of tumor regression following castration. Supplementary Figure 3: Gene Set Enrichment Analysis (GSEA). Supplementary Table 1: List of the primers used in this study. Supplementary Table 2: List of antibodies for used in this study. Supplementary Table 3: Summary of phenotypic analyses. Supplementary Table 7: Summary of preclinical data
Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC

Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo-Fu Hu,Philip W. Hinds

DOI: https://doi.org/10.1158/0008-5472.22396166

2023-01-01

Abstract:PDF file - 155K, Tumor formation in BRAFV600E/ARF-/- mice.
Supplementary Data from Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Yan Kong,Lu Si,Yanyan Zhu,Xiaowei Xu,Christopher L. Corless,Keith T. Flaherty,Li,Haifu Li,Xinan Sheng,Chuanliang Cui,Zhihong Chi,Siming Li,Mei Han,Lili Mao,Aiping Lu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22442474

2023-01-01

Abstract:Supplementary Figures S1-S8; Supplementary Tables S1-S3.
P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

C. Xu,W. Wang,Q. Zhang,W. Zhuang,Y. Zhu,Y. Chen,M. Fang,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.1198

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Activation of the platelet-derived growth factor (PDGF) signaling system has been implicated in the development and malignant progression of non-small-cell lung cancer. Recently, the platelet-derived growth factor receptor A (PDGFRA) gene mutations are identified in non-small-cell lung cancer (NSCLC). While the genetic locus of PDGFRA mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring PDGFRA mutations. A total of 467 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of PDGFRA mutation and other genes were detected by next generation sequencing. PDGFRA gene mutation rate was 2.14% (10/467) in non-small cell lung cancer, including S716R (1 patient), L615* (1 patient), A916T (1 patient), H104R (1 patient), V536M (1 patient), N505K (1 patient), V421I (1 patient), V538M (1 patient), M578K (1 patient) and V544A (1 patient), and median overall survival (OS) for these patients was 24.0 months. Among them, all patients were PDGFRA gene with co-occurring mutation. Briefly, patients with (n=2) or without (n=8) co-occurring EGFR mutations had a median OS of 19.0 months and 24.0 months respectively (P=0.96); patients with (n=6) or without (n=4) co-occurring TP53 mutations had a median OS of 24.0 months and 19.0 months respectively (P=0.99); patients with (n=2) or without (n=8) co-occurring BRCA2 mutations had a median OS of 25.0 months and 19.0 months respectively (P=0.17); patients with (n=2) or without (n=8) co-occurring IDH2 mutations had a median OS of 15.0 months and 24.0 months respectively (P=0.22). Mutation type of PDGFRA has a potential for predicting the course of the disease and might contribute to management individualization of NSCLC patients. EGFR, TP53, BRCA2 and IDH2 gene accompanied may have less correlation with PDGFRA mutation in NSCLC patients. Imatinib may displayed moderated efficacy in patients with PDGFRA mutation.
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Figure S1 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Data from Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure S1 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure from Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table S6 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Figure S1 from Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Data from Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure 3 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 2 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC